Cytokines and immunopathogenesis of intraocular posterior segment inflammation

Ocular Immunology and Inflammation

Volumn 11, Issue 1, 2003, Pages 17-28

  Dick, Andrew D ^a,b   Carter, Debra A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Microglia; TNFalpha; Uveitis

Indexed keywords

CD4 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; RETINA ANTIGEN; SOLUBLE CYTOKINE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DEVELOPED COUNTRY; EYE DISEASE; EYE INFECTION; EYE INJURY; GENETIC SUSCEPTIBILITY; GRANULOCYTE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION; INFLAMMATION; INTRAOCULAR POSTERIOR SEGMENT INFLAMMATION; MACROPHAGE; MICROGLIA; NUTRITIONAL STATUS; PATHOGENESIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TISSUE INJURY; UVEITIS; VISUAL IMPAIRMENT;

CYTOKINES; HUMANS; RECEPTORS, CYTOKINE; TH1 CELLS; UVEITIS, POSTERIOR;

EID: 0042165866     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.11.1.17.15575     Document Type: Review

References (72)

1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332-336.
2. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844-848.
3. Forrester JV. Duke-Elder lecture. New concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 1992;6:433-441.
4. Caspi RR, Roberge FG, McAllister CG, El-Saied M, Kuwabara T, Gery I, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986;136(3):928-933.
5. De Smet MD, Dayan M, Nussenblatt RB. A novel method for the determination of T-cell proliferative responses in patients with uveitis. Ocul Immunol Inflamm. 1998;6(3):173-178.
6. Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. Br J Ophthalmol. 1989;73(2):155-159.
7. Froebel KS, Armstrong SS, Cliffe AM, Urbaniak SJ, Forrester JV. An investigation of the general immune status and specific immune responsiveness to retinal-(S)-antigen in patients with chronic posterior uveitis. Eye. 1989;3(3):263-270.
8. Hirose S, Tanaka T, Nussenblatt RB, Palestine AG, Wiggert B, Redmond TM, et al. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects. Curr Eye Res. 1988;7(4):393-402.
9. Dick AD. Immune regulation of uveoretinal inflammation. Int Ophthalmol. 1999;30:187-202.
10. Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG. Experimental autoimmune uveoretinitis: a model system for immunointervention: a review. Curr Eye Res. 1992;II(Suppl):33-40.
11. Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol. 1999;83(11):1230-1234.
12. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000;84(1):107-109.
13. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13(1):114-119.
14. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumour immunity. Trends Immunol. 2002;23(4):210-218.
15. Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory. Immunology. 2000;99(3):334-337.
16. Granucci F, Andrews DM, Degli-Espoti MA, Ricciardi-Castagnoli. Il-2 mediated adjuvant effect of dendritic cells. Trends Immunol. 2002;23(4):169-171.
17. Black P. Why is the prevalence of allergy and autoimmunity increasing? Trends Immunol. 2001;22:354-355.
18. Shanks N, Harbuz MS, Jessop DS, Perks P, Moore PM, Lightman SL. Inflammatory disease as chronic stress. Ann NY Acad Sci. 1998;840:599-607.
19. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897-901.
20. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin. Trends Immunol. 2002;23(4):162-187.
21. Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol. 1992;148(8):2384-2389.
22. Davey MP, Rosenbaum JT. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol. 2000;129(2):235-243.
23. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens. 1999;54(3):264-272.
24. Seki N, Yamaguchi K, Yamada A, Kamizono S, Sugita S, Taguchi C, et al. Polymorphism of the 5′-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J Infect Dis. 1999;180(3):880-883.
25. Dick AD. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin. 2000;40(2):1-18.
26. Nussenblatt RB, Gery I, Weiner HL, Ferris FL, Shiloach J, Remaley N, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997;123(5):583-592.
27. Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci. 2001;42(6):1285-1292.
28. Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet's disease. Invest Ophthalmol Vis Sci. 1998;39(6):996-1004.
29. Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G. Serum interleukin 2-receptor levels in uveitis. Curr Eye Res. 1990;9(Suppl):25-29.
30. Scheinberg MA, Ikejiri M, Silva MH, Mota IM. Interleukin 2 receptor membrane bound and in soluble form in the aqueous humor and peripheral blood of patients with acute untreated uveitis. J Rheumatol. 1992;19(9):1362-1363.
31. Whitcup SM, Vistica BP, Magone MT, George RK. Elevated serum levels of soluble ICAM-1 in uveitis patients predict underlying systemic disease. Br J Ophthalmol. 1999;83(2):252-253.
32. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
33. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193(11):1303-1310.
34. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 2001;3(11):947-954.
35. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol. 2001;13(6):644-649.
36. Rhodes SG, Palmer N, Graham SP, Bianco AE, Hewinson RG, Vordermeier HM. Distinct response kinetics of gamma interferon and interleukin-4 in bovine tuberculosis. Infect Immun. 2000;68(9):5393-5400.
37. Rhodes SG, Graham SP. Is 'timing' important for cytokine polarisation. Trends Immunol. 2002;23(5):246-249.
38. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFNg production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22(10):556-560.
39. Forrester JV, Huitinga I, Lumsden L, Dijkstra CD. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res. 1998;17(4):426-437.
40. Caspi RR, Chan CC, Fujino Y, Najafian F, Grover S, Hansen CT, et al. Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis. J Neuroimmunol. 1993;47(2):177-188.
41. Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26(5):1018-1025.
42. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1998;11(3):255-264.
43. Smith JR, Hart PH, Coster DJ, Williams KA. Mice deficient in tumor necrosis factor receptors P55 and P75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1998;39(3):658-661.
44. Higuchi M, Diamantstein T, Osawa H, Caspi RR. Combined anti-interleukin-2 receptor and low-dose cyclosporine therapy in experimental autoimmune uveoretinitis. J Autoimmun. 1991;4(1):113-124.
45. + myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-g in autoimmune disease models. Trends Immunol. 2001;22(7):367-371.
46. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol. 1997;158(12):5997-6005.
47. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol. 1996;26(7):1641-1646.
48. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol. 1998;88(1):4-13.
49. Tarrant TK, Silver PB, Wahlsten JL, Rizzo LV, Chan CC, Wiggert B, et al. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med. 1999;189(2):219-230.
50. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990;172(4):1193-1200.
51. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185(9):1573-1584.
52. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15(4):533-543.
53. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37(7):1097-1102.
54. Liversidge J, Dick A, Gordon S. Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am J Pathol. 2002;160(3):905-916.
55. Silver PB, Tarrant TK, Chan CC, Wiggert B, Caspi RR. Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1999;40(6):1280-1284.
56. low parenchymal microglia. Br J Ophthalmol. 1995;79:834-840.
57. Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T lymphocyte final effector function and death. J Immunol. 1996;184:1737-1745.
58. Broderick C, Duncan L, Taylor N, Dick AD. IFN-gamma and LPS mediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci. 2000;41:2613-2622.
59. Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40(13):3177-3185.
60. Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Invest Ophthalmol Vis Sci. 2001;42(1):170-176.
61. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol. 1998;161(4):1983-1988.
62. Erwig LP, Rees AJ. Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Kidney Blood Press Res. 1999;22(1-2):21-25.
63. Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci. 2002;43(7):2250-2257.
64. Crane IJ, Kuppner MC, McKillop-Smith S, Wallace CA, Forrester JV. Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human retinal pigment epithelial cells. Clin Exp Immunol. 1999;115(2):288-293.
65. Crane IJ, Wallace CA, Forrester JV. Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-1beta and IFN-gamma. Cell Immunol. 2001;209(2):132-139.
66. Forrester JV, Liversidge J, Dick A, McMenamin P, Kuppner M, Crane I, et al. What determines the site of inflammation in uveitis and chorioretinitis? Eye. 1997;11(2):162-166.
67. Elliott MJ, Maini RN. Anti-cytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995;9(4):633-652.
68. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105-1110.
69. Kruithof E, Kestelyn P, Elewaut C, Elewaut D, Van Den Bosch F, Mielants H, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis. 2002;61(5):470.
70. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252-257.
71. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96(13):7462-7466.
72. Guex-Crosier Y, Raber J, Chan CC, Kriete MS, Benichou J, Pilson RS, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997;158(1):452-458.